Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.

MLA

Brunnberg, U., et al. “Induction Therapy of AML with Ara-C plus Daunorubicin versus Ara-C plus Gemtuzumab Ozogamicin: A Randomized Phase II Trial in Elderly Patients.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 23, no. 4, Apr. 2012, pp. 990–96. EBSCOhost, https://doi.org/10.1093/annonc/mdr346.

APA

Brunnberg, U., Mohr, M., Noppeney, R., Dürk, H. A., Sauerland, M. C., Müller-Tidow, C., Krug, U., Koschmieder, S., Kessler, T., Mesters, R. M., Schulz, C., Kosch, M., Büchner, T., Ehninger, G., Dührsen, U., Serve, H., & Berdel, W. E. (2012). Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 23(4), 990–996. https://doi.org/10.1093/annonc/mdr346

Chicago

Brunnberg, U, M Mohr, R Noppeney, H A Dürk, M C Sauerland, C Müller-Tidow, U Krug, et al. 2012. “Induction Therapy of AML with Ara-C plus Daunorubicin versus Ara-C plus Gemtuzumab Ozogamicin: A Randomized Phase II Trial in Elderly Patients.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 23 (4): 990–96. doi:10.1093/annonc/mdr346.